Through the specific cancer analysis, colorectal cancer patients (P = .0438) and head and neck cancer patients (P = .0276) harboring ARID1A mutations had longer OS than wild-type patients, while both ARID1A mutations (P = .0304) and ARID2 mutations (P = .0405) are suitable biomarkers for predicting the prognosis of melanoma patients. This evidence concerns the gene ARID1A and colorectal cancer.